Knoll Capital Management LLC's Q3 2023 13F: 12 new positions, 1 exit
Form 13F-HR for the quarter ended Sep 30, 2023 · filed Nov 14, 2023 · 37 reported positions · accession 0001104659-23-118123
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | Applied Therapeutics Inc (APLT) | 5.4% | 13.3% | +7.9 pts | +1.71M sh | +50% |
| New | Kinross Gold Corp (KGC) | — | 2.1% | +2.1 pts | +440K sh | new |
| New | Wheaton Precious Metals Corp (WPM) | — | 2.0% | +2.0 pts | +47,500 sh | new |
| New | Agnico Eagle Mines Ltd (AEM) | — | 1.9% | +1.9 pts | +40,000 sh | new |
| New | Equinox Gold Corp (EQX) | — | 1.8% | +1.8 pts | +421K sh | new |
| Increased | SEABRIDGE GOLD INC (SA) | 1.2% | 2.7% | +1.5 pts | +167K sh | +208% |
| New | Mag Silver Corp (MAG) | — | 1.7% | +1.7 pts | +160K sh | new |
| New | First Majestic Silver Corp (AG) | — | 1.5% | +1.5 pts | +275K sh | new |
| Increased | Silvercrest Metals Inc CAD (SILV) | 1.2% | 1.9% | +0.7 pts | +240K sh | +141% |
| Increased | Biohaven Pharmactl Hldg Co L (BHVN) | 13.2% | 13.2% | 0.0 pts | +40,000 sh | +9% |
| Increased | Avadel Pharmaceuticals Plc (AVDL) | 10.1% | 6.4% | −3.7 pts | +100K sh | +20% |
| Increased | Franco Nev Corp CAD (FNV) | 1.2% | 2.0% | +0.8 pts | +7,500 sh | +107% |
| New | Alamos Gold Inc (AGI) | — | 0.9% | +0.9 pts | +80,000 sh | new |
| New | Lockheed Martin Corp (LMT) | — | 0.9% | +0.9 pts | +2,150 sh | new |
| New | Royal Gold Inc. (RGLD) | — | 0.8% | +0.8 pts | +7,550 sh | new |
| New | Pan American Silver Corp (PAAS) | — | 0.8% | +0.8 pts | +54,085 sh | new |
| Exited | Altimmune Inc (ALT) | 0.8% | — | −0.8 pts | −174K sh | −100% |
| Reduced | Ocular Therapeutix Inc. (OCUL) | 1.3% | 0.0% | −1.3 pts | −200K sh | −100% |
| New | Amylyx (AMLX) | — | 0.5% | +0.5 pts | +24,772 sh | new |
| New | New Pac Metals Corp (NEWP) | — | 0.2% | +0.2 pts | +132K sh | new |
| Increased | Aldeyra Therapeutics Inc (ALDX) | 31.0% | 21.0% | −10.0 pts | +16,247 sh | +1% |
| Increased | BioXcell (BTAI) | 0.2% | 0.2% | −0.1 pts | +30,000 sh | +100% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 70.5% of the equity book
Changes in the top 10 this quarter: SA entered · KGC entered · ENTX left · GDXJ left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Aldeyra Therapeutics Inc (ALDX) | 31.0% | 21.0% | |
| 2 | Applied Therapeutics Inc (APLT) | 5.4% | 13.3% | |
| 3 | Biohaven Pharmactl Hldg Co L (BHVN) | 13.2% | 13.2% | |
| 4 | Avadel Pharmaceuticals Plc (AVDL) | 10.1% | 6.4% | |
| 5 | HOOKIPA PHARMA (HOOK) | 5.9% | 3.5% | |
| 6 | Verona Pharma (VRNA) | 5.2% | 3.4% | |
| 7 | SEABRIDGE GOLD INC (SA) | 1.2% | 2.7% | Entered the top 10 |
| 8 | Vaneck Gold Miners ETF (GDX) | 3.4% | 2.6% | |
| 9 | Global X Silver Miners ETF 37954Y848 (SIL) | 2.9% | 2.2% | |
| 10 | Kinross Gold Corp (KGC) | 0.0% | 2.1% | Entered the top 10 |
| — | Entera Bio Ltd (ENTX) | 2.6% | 1.9% | Left the top 10 |
| — | Vaneck Junior Gold Miners ETF (GDXJ) | 2.3% | 1.8% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).
Option positions (puts and calls)
Reported separately from the positions above. The value a 13F reports for an option is that of the underlying shares, not the option itself.
| Activity | Security | Type | Shares before | Shares now | Reported value |
|---|---|---|---|---|---|
| Exited | Ocular Therapeutix Inc. (OCUL) | Call | 95,800 | 0 | $0 |